CytomX Therapeutics (CTMX) Competitors $2.82 +0.12 (+4.44%) Closing price 06/11/2025 04:00 PM EasternExtended Trading$2.74 -0.07 (-2.66%) As of 08:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CTMX vs. CMRX, CDMO, NUVB, QURE, XERS, IMNM, PHAR, AVBP, NTLA, and CRONShould you be buying CytomX Therapeutics stock or one of its competitors? The main competitors of CytomX Therapeutics include Chimerix (CMRX), Avid Bioservices (CDMO), Nuvation Bio (NUVB), uniQure (QURE), Xeris Biopharma (XERS), Immunome (IMNM), Pharming Group (PHAR), ArriVent BioPharma (AVBP), Intellia Therapeutics (NTLA), and Cronos Group (CRON). These companies are all part of the "pharmaceutical products" industry. CytomX Therapeutics vs. Its Competitors Chimerix Avid Bioservices Nuvation Bio uniQure Xeris Biopharma Immunome Pharming Group ArriVent BioPharma Intellia Therapeutics Cronos Group Chimerix (NASDAQ:CMRX) and CytomX Therapeutics (NASDAQ:CTMX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, valuation, earnings, dividends, institutional ownership, risk, media sentiment, community ranking and analyst recommendations. Which has better valuation and earnings, CMRX or CTMX? CytomX Therapeutics has higher revenue and earnings than Chimerix. Chimerix is trading at a lower price-to-earnings ratio than CytomX Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChimerix$212K3,778.71-$82.10M-$0.99-8.63CytomX Therapeutics$147.56M1.54-$570K$0.485.88 Does the media prefer CMRX or CTMX? In the previous week, CytomX Therapeutics had 2 more articles in the media than Chimerix. MarketBeat recorded 2 mentions for CytomX Therapeutics and 0 mentions for Chimerix. CytomX Therapeutics' average media sentiment score of 1.71 beat Chimerix's score of 0.00 indicating that CytomX Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Chimerix Neutral CytomX Therapeutics Very Positive Which has more risk & volatility, CMRX or CTMX? Chimerix has a beta of -0.17, suggesting that its share price is 117% less volatile than the S&P 500. Comparatively, CytomX Therapeutics has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Is CMRX or CTMX more profitable? CytomX Therapeutics has a net margin of 10.96% compared to Chimerix's net margin of 0.00%. CytomX Therapeutics' return on equity of -41.47% beat Chimerix's return on equity.Company Net Margins Return on Equity Return on Assets ChimerixN/A -50.78% -44.94% CytomX Therapeutics 10.96%-41.47%8.11% Does the MarketBeat Community believe in CMRX or CTMX? Chimerix received 17 more outperform votes than CytomX Therapeutics when rated by MarketBeat users. However, 65.46% of users gave CytomX Therapeutics an outperform vote while only 62.66% of users gave Chimerix an outperform vote. CompanyUnderperformOutperformChimerixOutperform Votes39662.66% Underperform Votes23637.34% CytomX TherapeuticsOutperform Votes37965.46% Underperform Votes20034.54% Do insiders and institutionals hold more shares of CMRX or CTMX? 45.4% of Chimerix shares are held by institutional investors. Comparatively, 67.8% of CytomX Therapeutics shares are held by institutional investors. 13.1% of Chimerix shares are held by company insiders. Comparatively, 6.6% of CytomX Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Do analysts rate CMRX or CTMX? Chimerix presently has a consensus price target of $8.53, indicating a potential downside of 0.08%. CytomX Therapeutics has a consensus price target of $5.33, indicating a potential upside of 89.13%. Given CytomX Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CytomX Therapeutics is more favorable than Chimerix.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chimerix 0 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00CytomX Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryCytomX Therapeutics beats Chimerix on 15 of the 18 factors compared between the two stocks. Get CytomX Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTMX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTMX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTMX vs. The Competition Export to ExcelMetricCytomX TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$227.35M$6.85B$5.57B$8.63BDividend YieldN/A2.55%5.28%4.18%P/E Ratio16.598.7827.1420.06Price / Sales1.54255.64411.98157.10Price / CashN/A65.8538.2534.64Price / Book-3.976.557.064.70Net Income-$570K$143.93M$3.23B$247.88M7 Day Performance17.50%3.84%2.85%2.63%1 Month Performance32.39%11.20%9.06%6.36%1 Year Performance89.26%4.18%31.43%14.05% CytomX Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTMXCytomX Therapeutics4.3057 of 5 stars$2.82+4.4%$5.33+89.1%+89.3%$227.35M$147.56M16.59170Positive NewsCMRXChimerix0.7182 of 5 stars$8.54flat$8.53-0.1%N/A$801.09M$212K-9.0990CDMOAvid Bioservices0.877 of 5 stars$12.50+0.1%$12.25-2.0%+56.4%$799.18M$139.91M-5.23320High Trading VolumeNUVBNuvation Bio3.0003 of 5 stars$2.34+10.1%$7.83+235.5%-22.5%$794.51M$10.96M-1.0860Trending NewsAnalyst ForecastHigh Trading VolumeQUREuniQure2.0725 of 5 stars$14.48+0.1%$37.82+161.2%+210.1%$793.16M$20.20M-2.92500News CoverageAnalyst RevisionXERSXeris Biopharma3.9284 of 5 stars$5.05+2.2%$6.25+23.8%+90.4%$789.74M$222.55M-11.22290Analyst RevisionIMNMImmunome1.7981 of 5 stars$9.06+3.4%$23.33+157.5%-39.6%$788.33M$10.94M-1.1240Positive NewsPHARPharming Group2.0663 of 5 stars$11.48+8.3%$30.00+161.3%+32.9%$781.00M$320.71M-44.15280News CoverageShort Interest ↑AVBPArriVent BioPharma1.4582 of 5 stars$22.00+3.5%$39.29+78.6%+24.4%$752.69MN/A-5.8440Positive NewsHigh Trading VolumeNTLAIntellia Therapeutics4.5892 of 5 stars$7.16+4.2%$36.75+413.3%-64.8%$741.65M$45.57M-1.32600Analyst RevisionGap UpHigh Trading VolumeCRONCronos Group1.9294 of 5 stars$1.92-3.0%N/A-21.0%$739.98M$124.59M-14.77450Positive News Related Companies and Tools Related Companies Chimerix Competitors Avid Bioservices Competitors Nuvation Bio Competitors uniQure Competitors Xeris Biopharma Competitors Immunome Competitors Pharming Group Competitors ArriVent BioPharma Competitors Intellia Therapeutics Competitors Cronos Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTMX) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMarch 16th -- America’s most important day?50-Year Legend: Here's The Day Stocks Likely Crash Legendary quant analyst Marc Chaikin says in 50 years on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CytomX Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CytomX Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CTMX Stock Free CTMX Stock Alerts